tbuckley/cabot-search huggingface dataset:
Exploring pericyte and cardiac stem cell secretome unveils new tactics for drug discovery
Authors: Georgina M. Ellison-Hughes, Paolo Madeddu
Journal: Pharmacology & Therapeutics (2016)

Ischaemic diseases remain a major cause of morbidity and mortality despite continuous advancements in medical and interventional treatments. Moreover, available drugs reduce symptoms associated with tissue ischaemia, without providing a definitive repair. Cardiovascular regenerative medicine is an expanding field of research that aims to improve the treatment of ischaemic disorders through restorative methods, such as gene therapy, stem cell therapy, and tissue engineering. Stem cell transplantation has salutary effects through direct and indirect actions, the latter being attributable to growth factors and cytokines released by stem cells and influencing the endogenous mechanisms of repair. Autologous stem cell therapies offer less scope for intellectual property coverage and have limited scalability. On the other hand, off-the-shelf cell products and derivatives from the stem cell secretome have a greater potential for large-scale distribution, thus enticing commercial investors and reciprocally producing more significant medical and social benefits. This review focuses on the paracrine properties of cardiac stem cells and pericytes, two stem cell populations that are increasingly attracting the attention of regenerative medicine operators. It is likely that new cardiovascular drugs are introduced in the next future by applying different approaches based on the refinement of the stem cell secretome.
Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting &gt; 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas
Authors: Mark S. Kaminski, Andrew D. Zelenetz, Oliver W. Press, Mansoor N. Saleh, John P. Leonard, Louis Fehrenbacher, T. Andrew Lister, Thierry J. Horner, Vanessa C. Williams, Thomas S. Lin, Christina Vleisides, Susan J. Knox, Richard L. Wahl, Julie M. Vose
Journal: Blood (2010)
Conversion of Low Donor Chimerism Following Nonmyeloablative Conditioning for Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusion (DLI).
Authors: Brenda M. Sandmaier, David G. Maloney, Michael B. Maris, Thomas R. Chauncey, Michael Pulsipher, Wolfgang Bethge, Marie-Terese Little, Rainer Storb
Journal: Blood (2004)
High-Throughput Screening of a Large Combinatorial Library of Small Proteins Against Human Spleen-Derived Monoclonal Anti-ADAMTS13 Antibodies Yields Specific Anti-Idiotypic Molecules – Potential Tools for New Treatment Strategy in Acquired TTP
Authors: Monica Schaller, Sabine Hiltbrunner, Irmela Sulzer, Monique Vogel, Karim Kentouche, Bernhard Laemmle, Johanna A. Kremer Hovinga
Journal: Blood (2012)
Autologous Stem Cell Transplantation In Mantle Cell Lymphoma: Total Body Irradiation (TBI) Plus Cyclophosphamide (or Melphalan) Is Not Superior to BEAM, A Single Institution Experience
Authors: Pierre Peterlin, Christophe Leux, Thomas Gastinne, Beatrice Mahe, Viviane Dubruille, Jacques Delaunay, Patrice Chevallier, Thierry Guillaume, Nicolas Blin, Sameh Ayari, irginie Roland, Mohamad Mohty, Noel Milpied, Jean-Luc Harousseau, Philippe Moreau, Steven Le Gouill
Journal: Blood (2010)
The Use of Day 14 Bone Marrow Characteristics in the Decision to Pursue a Second Course of Induction Chemotherapy in the Treatment of Acute Myeloid Leukemia.
Authors: Masumi Ueda, Hu Xie, Ravinder K Sandhu, Roland B. Walter, John M. Pagel, Pamela S. Becker, Janis L. Abkowitz, Elihu H. Estey
Journal: Blood (2012)
Leukocyte Telomere Length in Relation to 17 Biomarkers of Cardiovascular Disease Risk: A Cross-Sectional Study of US Adults
Authors: David H. Rehkopf, Belinda L. Needham, Jue Lin, Elizabeth H. Blackburn, Ami R. Zota, Janet M. Wojcicki, Elissa S. Epel
Journal: PLoS Medicine (2016)

Background Leukocyte telomere length (LTL) is a putative biological marker of immune system age, and there are demonstrated associations between LTL and cardiovascular disease. This may be due in part to the relationship of LTL with other biomarkers associated with cardiovascular disease risk. However, the strength of associations between LTL and adiposity, metabolic, proinflammatory, and cardiovascular biomarkers has not been systematically evaluated in a United States nationally representative population. Methods and Findings We examined associations between LTL and 17 cardiovascular biomarkers, including lipoproteins, blood sugar, circulatory pressure, proinflammatory markers, kidney function, and adiposity measures, in adults ages 20 to 84 from the cross-sectional US nationally representative 1999–2002 National Health and Nutrition Examination Survey (NHANES) (n = 7,252), statistically adjusting for immune cell type distributions. We also examine whether these associations differed systematically by age, race/ethnicity, gender, education, and income. We found that a one unit difference in the following biomarkers were associated with kilobase pair differences in LTL: BMI -0.00478 (95% CI -0.00749–-0.00206), waist circumference -0.00211 (95% CI -0.00325–-0.000969), percentage of body fat -0.00516 (95% CI -0.00761–-0.0027), high density lipoprotein (HDL) cholesterol 0.00179 (95% CI 0.000571–0.00301), triglycerides -0.000285 (95% CI -0.000555–-0.0000158), pulse rate -0.00194 (95% CI -0.00317–-0.000705), C-reactive protein -0.0363 (95% CI 0.0601–-0.0124), cystatin C -0.0391 (95% CI -0.0772–-0.00107). When using clinical cut-points we additionally found associations between LTL and insulin resistance -0.0412 (95% CI -0.0685–-0.0139), systolic blood pressure 0.0455 (95% CI 0.00137–0.0897), and diastolic blood pressure -0.0674 (95% CI -0.126–-0.00889). These associations were 10%–15% greater without controlling for leukocyte cell types. There were very few differences in the associations by age, race/ethnicity, gender, education, or income. Our findings are relevant to the relationships between these cardiovascular biomarkers in the general population but not to cardiovascular disease as a clinical outcome. Conclusions LTL is most strongly associated with adiposity, but is also associated with biomarkers across several physiological systems. LTL may thus be a predictor of cardiovascular disease through its association with multiple risk factors that are physiologically correlated with risk for development of cardiovascular disease. Our results are consistent with LTL being a biomarker of cardiovascular aging through established physiological mechanisms.
Hormonal Contraception and Risk of Thromboembolism in Women With Diabetes
Authors: Sarah H. O’Brien, Terah Koch, Sara K. Vesely, Eleanor Bimla Schwarz
Journal: Diabetes Care (2016)

To investigate safety of hormonal contraception with regard to thromboembolic events in women with type 1 or 2 diabetes.We used data from 2002-2011 in Clinformatics Data Mart to identify women in the U.S., 14-44 years of age, with an ICD-9-CM code for diabetes and a prescription for a diabetic medication or device. We examined contraceptive claims and compared time to thromboembolism (venous thrombosis, stroke, or myocardial infarction) among women with diabetes dispensed hormonal contraception using a modification of Cox regression to control for age, smoking, obesity, hypertension, hyperlipidemia, diabetic complications, and history of cancer; we excluded data for 3 months after women gave birth.We identified 146,080 women with diabetes who experienced 3,012 thromboembolic events. Only 28% of reproductive-aged women with diabetes had any claims for hormonal contraception, with the majority receiving estrogen-containing oral contraceptives. Rates of thromboembolism were highest among women who used the contraceptive patch (16 per 1,000 woman-years) and lowest among women who used intrauterine (3.4 per 1,000 woman-years) and subdermal (0 per 163 woman-years) contraceptives. Compared with use of intrauterine contraception, progestin-only injectable contraception was associated with increased risk of thromboembolism (12.5 per 1,000 woman-years; adjusted hazard ratio 4.69 [95% CI 2.51-8.77]).The absolute risk of thromboembolism among women with type 1 or 2 diabetes using hormonal contraception is low. Highly effective, intrauterine and subdermal contraceptives are excellent options for women with diabetes who hope to avoid the teratogenic effects of hyperglycemia by carefully planning their pregnancies.
Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Paul A. Hamlin, Maria Alma Rodriguez, Ariela Noy, Carol S. Portlock, David Straus, Peter McLaughlin, Barbara Pro, Luis Fayad, Frederick Hagemeister, Brett Wegner, Otilia Dumitrescu, Neetha Pandit Tasker, Craig H Moskowitz, Andrew D Zelenetz
Journal: Blood (2010)
Allogeneic Hematopoietic Stem Cell Transplantation as Consolidation Therapy for Adult T Cell Leukemia/Lymphoma Patients: A Single-Center Experience in 35 Patients.
Authors: Shigeki Takemoto, Michihiro Hidaka, Shoichi Nagakura, Tatsunori Sakai, Takahiro Matsui, Toshiro Kawakita, Yoshiko Inoue, Atsuko Tsukamoto, Tetsuyuki Kiyokawa, Fumio Kawano
Journal: Blood (2007)
Cytoprotective Effect of Palifermin on Gastrointestinal Mucous Membrane Enabled Non-Myeloablative Chemotherapy Administration in ALL Patient with High Risk of Gastrointestinal Toxicity.
Authors: Kajetana Foryciarz, Tomasz Sacha, Patrycja Mensah-Glanowska, Agnieszka Balana-Nowak, Aleksander Skotnicki
Journal: Blood (2007)
CDR3-Independent Expansion of Vδ1 γδ T Lymphocytes and Depletion of Vδ2 T Cells Are Unique Features in Acquired Chronic Pure Red Cell Aplasia,
Authors: Michishita Yoshihiro, Makoto Hirokawa, Naohito Fujishima, Yukiko Abe, Masumi Fujishima, Yong-Mei Guo, Kumi Ubukawa, Liu Jiajia, Tomoko Yoshioka, Yoshihiro Kameoka, Hirobumi Saitoh, Hiroyuki Tagawa, Naoto Takahashi, Kenichi Sawada
Journal: Blood (2011)
Detailed Genome-Wide DNA-Mapping of CD34+ Cells Purified from Patients with MDS Using High-Resolution SNP Arrays Identifies Significant Regions of Genomic Alterations.
Authors: Daniel Nowak, Florian Wagner, Claudia C. Baldus, Olaf Hopfer, Maximilian Mossner, Verena Serbent, Eckhard Thiel, Wolf K. Hofmann
Journal: Blood (2006)
Poster Board III-457 Surface Plasmon Resonance (SPR) Analysis Detects Clinically Significant Low Avidity HPA-1a Antibodies Not Identified by Conventional Serology.
Authors: Julie A. Peterson, Adam Kanack, Maria L. Gitter, Vipul Rathore, Janice McFarland, Brian R Curtis, Richard H. Aster
Journal: Blood (2009)
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
Authors: Kenneth I. Ataga, Abdullah Kutlar, Julie Kanter, Darla Liles, Rodolfo Cancado, João Friedrisch, Troy H. Guthrie, Jennifer Knight-Madden, Ofelia A. Alvarez, Victor R. Gordeuk, Sandra Gualandro, Marina P. Colella, Wally R. Smith, Scott A. Rollins, Jonathan W. Stocker, Russell P. Rother
Journal: New England Journal of Medicine (2016)

The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell–cell interactions that are involved in the pathogenesis of vaso-occlusion and sickle cell–related pain crises. The safety and efficacy of crizanlizumab, an antibody against the adhesion molecule P-selectin, were evaluated in patients with sickle cell disease.
Tumor Cell-Dependent Differences in Stroma-Induced Changes to Bortezomib Sensitivity.
Authors: Eugen Dhimolea, Jana Jakubikova, Richard W.J. Groen, Jake E. Delmore, Hannah M. Jacobs, Douglas W. McMilllin, Ana Acuña-Villaorduña, Catriona A. Hayes, Panisinee Lawasut, Constantine S. Mitsiades
Journal: Blood (2012)
Metabolic Fate of Oral Glutamine Supplementation within Plasma and Erythrocytes of Patients with Sickle Cell Disease: Preliminary Pharmacokinetics Results
Authors: Claudia R. Morris, Frans Kuypers, Robert W Hagar, Michael Ansari, Sandra K Larkin, Lisa Lavrisha, Meghan Wardlaw, Alicia Zhou, Elliott Vichinsky, Jung H Suh
Journal: Blood (2010)
Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.
Authors: Mamta Gupta, Guangzhen Hu, Steven Offer, Matthew J Maurer, Linda Wellik, Jing Jing Han, Ahmet Dogan, Robert B. Diasio, Thomas E. Witzig
Journal: Blood (2012)
Clinical Outcomes in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (TTP) Who Received Platelet Transfusions (PT).
Authors: Karen K. Swisher, Johanna A. Kremer Hovinga, Bernhard Lämmle, Deirdra R. Terrell, Sara K. Vesely, James N. George
Journal: Blood (2007)
Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial)
Authors: Alexander Röth, Martin Bommer, Andreas Hüttmann, Dörte Herich-Terhürne, Nils Kuklik, Lenz Veronika, Hubert Schrezenmeier, Ulrich Dührsen
Journal: Blood (2015)
Role of Hematopoietic Stem Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated with All-Trans-Retinoic Acid: A Retrospective Analysis of the Japan Adult Leukemia Study Group (JALSG) APL97 Study
Authors: Hiroyuki Fujita, Norio Asou, Masako Iwanaga, Rie Hyo, Shosaku Nomura, Hitoshi Kiyoi, Masaya Okada, Motohiro Tsuzuki, Mitsuhiro Matsuda, Takahiro Yamauchi, Shigeki Ohtake, Tohru Izumi, Chiaki Nakaseko, Kinuko Mitani, Katsuji Shinagawa, Akihiro Takeshita, Yasushi Miyazaki, Kazunori Ohnishi, Shuichi Miyawaki, Tomoki Naoe
Journal: Blood (2011)
Phase II Activity of the HSP90 Inhibitor AUY922 in Patients with Alk-Rearranged (ALK+) or Egfr-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: E. Felip, E. Carcereny, F. Barlesi, L. Gandhi, L.V. Sequist, S.-W. Kim, H.J.M. Groen, B. Besse, D.-W. Kim, E. Smit, M. Akimov, E. Avsar, S. Bailey, W. Ofosu-Appiah, E.B. Garon
Journal: Annals of Oncology (2012)
Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study
Authors: Corentin Orvain, Marie Balsat, Veronique Lheritier, Emmanuelle Tavernier, Jean-Pierre Marolleau, Thomas Pabst, Patrice Chevallier, Noemie de Gunzburg, Victoria Cacheux, Francoise Huguet, Sylvain Chantepie, Denis Caillot, Yves Chalandon, Jamile Frayfer, Caroline Bonmati, Nicolas Boissel, Herve Dombret, Norbert Ifrah, Mathilde Hunault-Berger
Journal: Blood (2016)
Diagnostic Utility of CD200 and CD43 Co-Expression by Flow Cytometry In Differentiating Chronic Lymphocytic Lymphoma From Other of Mature B Cell Non Hodgkin's Lymphoma.
Authors: Papagudi Ganesan Subramanian, Vijaya Siddharth Gadage, Ashok Kumar, Yajamanam Badrinath, Sitaram Ghogale, Tanuja Shet, Pratibha AmareKadam, Reena Nair, Sumeet Gujral
Journal: Blood (2010)
Genome-Wide Analysis of EKLF Occupancy in Erythroid Chromatin Reveals 5′, 3′ and Intragenic Binding Sites in EKLF Target Genes
Authors: Andre M. Pilon, Elliott H. Margulies, Hatice Ozel Abaan, Amy Werner- Allen, Tim M. Townes, Abbie M. Frederick, Dewang Zhou, Patrick G. Gallagher, David M. Bodine
Journal: Blood (2008)
Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.
Authors: Roberto Sorasio, Luisa Giaccone, Francesca Patriarca, Vittorio Montefusco, Stefano Guidi, Alessandro Busca, Rosanna Scime’, Giuseppe Console, Giuseppe Milone, Giuseppe Marotta, Alida Dominietto, Marcello Rotta, Michele Falda, Andrea Bacigalupo, Alberto Bosi, Paolo Corradini, Renato Fanin, Simona Pollichieni, Benedetto Bruno, Mario Boccadoro
Journal: Blood (2006)
Response Adapted Induction Therapy for Multiple Myeloma
Authors: Jason Valent, Christy Samaras, Debbie Hastings, Beth M Faiman, Kimberly Hamilton, Brian J. Bolwell, Janice Reed, Mary Ann Karam, Chad Cummings, Katherine Tullio, Mitchell R. Smith, Hien K. Liu, Frederic J Reu
Journal: Blood (2015)
Health Cost Modelisation of Home Versus Hospital Administration of Bortezomib. Experience of a French Hematologic Care Network
Authors: Mohamed Touati, Ludovic Lamarsalle, Stephane Moreau, Sophie Lefort, Liliane Remenieras, Catherine Brillat, Francoise Vergnenegre, Aline Lagarde, Annick Daulange, Véronique Gatard, Alain Vergnenegre, Dominique Bordessoule
Journal: Blood (2012)
The Gene RUNX1 and Its Possible Relation with the Alteration of Granulocytes Cells and with the Progression of Chronic Myeloid Leukemia.
Authors: Cintia C Mascarenhas, Anderson Ferreira Cunha, Ana Flavia Brugnerotto, Sheley Gambero, Fernando Ferreira Costa, Katia Borgia Barbosa Pagnano, Carmino Antonio De Souza
Journal: Blood (2009)
Human γδT-cell subsets and their involvement in tumor immunity
Authors: Dang Wu, Pin Wu, Fuming Qiu, Qichun Wei, Jian Huang
Journal: Cellular and Molecular Immunology (2016)

γδT cells are a conserved population of innate lymphocytes with diverse structural and functional heterogeneity that participate in various immune responses during tumor progression. γδT cells perform potent immunosurveillance by exerting direct cytotoxicity, strong cytokine production and indirect antitumor immune responses. However, certain γδT-cell subsets also contribute to tumor progression by facilitating cancer-related inflammation and immunosuppression. Here, we review recent observations regarding the antitumor and protumor roles of major structural and functional subsets of human γδT cells, describing how these subsets are activated and polarized, and how these events relate to subsequent function in tumor immunity. These studies provide insights into the manipulation of γδT-cell function to facilitate more targeted approaches for tumor therapy.
Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree
Authors: Richard J. Sylvester, Steven E. Canfield, Thomas B.L. Lam, Lorenzo Marconi, Steven MacLennan, Yuhong Yuan, Graeme MacLennan, John Norrie, Muhammad Imran Omar, Harman M. Bruins, Virginia Hernández, Karin Plass, Hendrik Van Poppel, James N’Dow
Journal: European Urology (2016)
FLT3, PIM and CXCR4 Expression In Acute Myeloid Leukemia
Authors: Rafael Alonso Fernández, Inmaculada Rapado, Castro Nerea, Pilar Martinez-Sanchez, Ascensión Peña, Luis Garcia-Alonso, Montserrat Rubio, Antonia Rodriguez, Maria del Pilar Martinez-Barranco, Maria del Carmen Calle, Maria Jose Otero, Juan Carlos Ponce, Florinda Gilsanz-Rodriguez, Rosa M. Ayala, Joaquin Martinez-Lopez
Journal: Blood (2013)
NEOD001 Specifically Binds Aggregated Light Chain Infiltrates in Multiple Organs from Patients with AL Amyloidosis and Promotes Phagocytic Clearance of AL Aggregates in Vitro
Authors: Wagner Zago, Mark Renz, Ronald Torres, Philip J. Dolan, Robin M. Barbour, Joshua R. Salmans, Paul J. Shughrue, Dale Schenk, Gene G. Kinney
Journal: Blood (2015)
Blocking of IL-21 Signal Attenuates Graft-Versus-Host Disease but Not Graft-Versus-Leukemia Effect in a Mouse Model
Authors: Akiko Meguro, Katsutoshi Ozaki, Iekuni Oh, Haruko Matsu, Keiko Hatanaka, Raine Tatara, Warren J Leonard, Kazuya Sato, Keiya Ozawa
Journal: Blood (2008)
Hypoxia Inducible Factor-1α Is over Expressed in CLL B Cells Because of an Impaired Proteasome Pathway Associated with Defective Interaction with von Hippel-Landau Protein.
Authors: Yean K. Lee, Ann K. Strege, Nancy D. Bone, Linda E. Wellik, D. A. Chan, A. J. Giaccia, Debabrata Mukhopadhyay, Neil E. Kay
Journal: Blood (2005)
Mitochondrial Haplotype As an Independent Predictor of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Authors: Julie A. Ross, Jakub Tolar, Logan G. Spector, Todd E. Defor, Troy C. Lund, Daniel J. Weisdorf, Anthony J. Hooten, Bharat Thyagarajan, Erica Langer, Michelle K. Gleason, John E Wagner, Kimberly Robien, Michael R. Verneris
Journal: Blood (2014)
Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
Authors: Amalia Gastaldelli, Melania Gaggini, Giuseppe Daniele, Demetrio Ciociaro, Eugenio Cersosimo, Devjit Tripathy, Curtis Triplitt, Peter Fox, Nicolas Musi, Ralph DeFronzo, Patricia Iozzo
Journal: Hepatology (2016)

Glucagon‐like peptide 1 (GLP‐1) receptor agonists (GLP‐1‐RAs) act on multiple tissues, in addition to the pancreas. Recent studies suggest that GLP‐1‐RAs act on liver and adipose tissue to reduce insulin resistance (IR). Thus, we evaluated the acute effects of exenatide (EX) on hepatic (Hep‐IR) and adipose (Adipo‐IR) insulin resistance and glucose uptake. Fifteen male subjects (age = 56 ± 8 years; body mass index = 29 ± 1 kg/m 2 ; A1c = 5.7 ± 0.1%) were studied on two occasions, with a double‐blind subcutaneous injection of EX (5 μg) or placebo (PLC) 30 minutes before a 75‐g oral glucose tolerance test (OGTT). During OGTT, we measured hepatic (HGU) and adipose tissue (ATGU) glucose uptake with [ 18 F]2‐fluoro‐2‐deoxy‐D‐glucose/positron emission tomography, lipolysis (RaGly) with [U‐ 2 H 5 ]‐glycerol, oral glucose absorption (RaO) with [U‐ 13 C 6 ]‐glucose, and hepatic glucose production (EGP) with [6,6‐ 2 H 2 ]‐glucose. Adipo‐IR and Hep‐IR were calculated as (FFA 0‐120min ) × (Ins 0‐120min ) and (EGP 0‐120min ) × (Ins 0‐120min ), respectively. EX reduced RaO, resulting in reduced plasma glucose and insulin concentration from 0 to 120 minutes postglucose ingestion. EX decreased Hep‐IR (197 ± 28 to 130 ± 37; P = 0.02) and increased HGU of orally administered glucose (23 ± 4 to 232 ± 89 [μmol/min/L]/[μmol/min/kg]; P = 0.003) despite lower insulin (23 ± 5 vs. 41 ± 5 mU/L; P &lt; 0.02). EX enhanced insulin suppression of RaGly by decreasing Adipo‐IR (23 ± 4 to 13 ± 3; P = 0.009). No significant effect of insulin was observed on ATGU (EX = 1.16 ± 0.15 vs. PLC = 1.36 ± 0.13 [μmol/min/L]/[μmol/min/kg]). Conclusion: Acute EX administration (1) improves Hep‐IR, decreases EGP, and enhances HGU and (2) reduces Adipo‐IR, improves the antilipolytic effect of insulin, and reduces plasma free fatty acid levels during OGTT. (H epatology 2016;64:2028‐2037).
L-Asparaginase-Loaded Red Blood Cells Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph- ALL): First Results of the GRASPALL/GRAALL-SA2-2008 Study
Authors: Mathilde Hunault, Thibault Legay, Françoise Huguet, Stéphane Leprêtre, Eric Deconinck, Mario Ojeda Uribe, Caroline Bonmati, Bruno Lioure, Catherine Himberlin, Patrice Chevallier, Philippe Rousselot, Oumedaly Reman, Marie-Laure Boulland, Véronique Lhéritier, Severine Lissandre, Pascal Turlure, Didier Bouscary, Laurence Sanhes, Ollivier Legrand, Isabelle Plantier, Frédérique Orsini Piocelle, David Liens, Yann Godfrin, Norbert Ifrah, Herve Dombret
Journal: Blood (2011)
Children’s Environmental Health: Homes of Influence
Authors: Brenda Afzal, Nsedu Obot Witherspoon, Kristie Trousdale
Journal: Environmental Health Perspectives (2016)

Summary:Over the past two decades, diverse stakeholder groups, representing various disciplines and perspectives (e.g., federal, state and local policy makers; nonprofit organizations; health professionals; and industry), have devoted considerable resources, expertise, and influence toward efforts that wittingly and unwittingly affect children’s environmental health. In this article, we refer to these groups as “homes of influence,” and we summarize the wide reach and potential impacts of these homes on childhood asthma, as one example that illustrates how these varied groups impact childhood health outcomes. We posit that diverse homes of influence can be most successful in effecting positive change when they understand and acknowledge their respective influences and work together to develop informed, preventive initiatives under the framework of recommendations called, “A Blueprint for Protecting Children’s Environmental Health: An Urgent Call to Action.” This published resource was developed by a panel of thought leaders and experts in the field of children’s environmental health to guide cross-sector collaboration efforts to proactively protect the environmental health of all children.